Bio-Rad Laboratories, Inc. Class A Common Stock vs Nebius Group NV — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Nebius Group NV trades at $217.32 (market cap $49.06B). The key difference: Nebius Group NV is far larger — about 5.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| BIO | NBIS | |
|---|---|---|
Market Cap | $9.43B | $49.06B |
Sector | Health | Technology |
52-Week High | $356.25 | $286.69 |
52-Week Low | $241.71 | $64.06 |
Enterprise Value | $9.18B | $49.26B |
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →